1. South Korea Stocks

  2. •

    Process industries

  3. •

    Chemicals: specialty
NPK Co., Ltd

NPK Co., Ltd

KKRX:048830
960.00
KRW
+7.00
(+0.73%)
45.00EPS
22.87P/E
19.24BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
6,490.35
4,882.42
4,208.9
4,792.3
5,229.03
3,568.09
3,343.14
3,330.94
3,430.65
3,481.27
3,346.24
3,451.13
4,447.3
4,604.25
Basic EPS, GAAP
198.81
6.41
-56.8
131.93
130
-14
-45
-33
106
79
91
-45
60
45
Free Cash Flow per Basic Share
468.74
-92.59
-1,099.43
298.72
221.78
-413.02
-449.34
59.48
116.33
320.5
316.1
-25.21
13.45
-21
Dividend per Share
27.43
37.01
27.57
27.49
27.68
29.75
30.32
30.32
29.8
29.95
29.8
29.98
29.76
- -
Book Value per Share
2,160.33
2,134.99
2,068.65
2,201.21
2,278.14
2,184.01
2,156.49
2,076.5
2,298.34
2,343
2,377.63
2,410.56
2,472.84
2,493.07
Tangible Book Value per Share
2,081.72
2,078.33
2,013.74
2,134.48
2,224.64
1,958.63
1,946.38
1,872.41
2,083.09
2,312.16
2,349.31
2,375.44
2,440.27
2,460.73
Basic Weighted Avg Shares
10
13
14
14
14
19
18
18
19
19
19
19
19
19
Sales/Revenue/Turnover
67,413
62,639
59,070
67,438
73,093
67,275
61,832
61,611
64,566
65,201
62,988
64,566
83,822
86,111
Operating Margin (%)
2.12
0.46
-3.7
0.5
2.77
0.13
2.55
0.82
3.65
2.2
2.97
-0.98
1.21
0.94
Depreciation Expense
2,265
2,363
2,666
3,735
4,265
4,527
4,423
5,707
5,420
5,586
5,443
5,186
5,176
5,091
Net Income, GAAP
2,065
82
-797
1,857
1,817
-264
-832
-610
1,995
1,480
1,713
-842
1,131
842
Effective Tax Rate (%)
7.81
85.9
- -
- -
6.45
239
19.49
192.41
18.18
53.73
26.62
- -
25.93
44.24
Profit Margin (%)
3.06
0.13
-1.35
2.75
2.49
-0.39
-1.35
-0.99
3.09
2.27
2.72
-1.3
1.35
0.98
Working Capital
8,851
10,675
5,325
7,250
15,836
20,797
12,591
5,107
3,093
4,327
10,067
12,582
15,742
16,098
LT Debt
2,845
2,054
9,018
10,008
6,023
13,925
13,681
8,432
4,227
541
202
229
174
108
Total Equity
22,982
30,701
29,740
31,628
43,236
41,476
40,316
38,821
42,968
43,803
44,451
45,066
46,231
46,609
Return on Invested Capital (%)
4.76
0.13
- -
- -
3.8
-0.23
2.31
-0.85
3.47
1.2
2.66
- -
1.47
0.86
Return on Capital (%)
8.12
0.19
- -
- -
4.19
-1.23
-0.91
-1.77
4.21
2.99
3.63
- -
2.4
1.69
Return on Common Equity (%)
9.51
0.31
-2.69
6.18
4.94
-0.63
-2.05
-1.54
4.88
3.41
3.88
-1.88
2.48
1.85

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
5,808
5,905
8,278
LT Borrowings
- -
- -
- -
LT Finance Leases
240
174
108
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
19
19
19
Market Capitalization
20,341
17,705
19,238

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
26,605
29,201
36,123
Cash, Cash Equivalents & STI
11,170
13,909
13,338
Accounts Receivable, Net
8,312
8,649
11,148
Inventories
5,089
4,573
8,237
Total Current Liabilities
14,153
13,459
20,025
Payables & Accruals
- -
- -
- -
ST Debt
5,808
5,905
8,278
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.05%
3.61%
2.58%
Free Cash Flow
-60.06%
2.12%
-153.74%
Net Income, GAAP
-108.13%
-164.08%
-234.33%
Sales/Revenue/Turnover
4.09%
6.94%
29.82%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
15,818
15,763
15,169
17,815
64,566
2025
19,941
20,943
20,651
22,288
83,822
2026
22,230
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-10
1
-17
-19.31
-45
2025
-11
33.03
-30.19
68.09
60
2026
-26.02
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
29.98
2025
- -
- -
- -
- -
29.76
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yun-Hyeok Choi
Full Time Employees
237
Sector
Process industries
Industry
Chemicals: specialty
Address
Gumi South Korea
IPO Date
Oct 12, 2000
Website
npk.co.kr
Similar Companies
Petkim Petrokimya Holding Anonim Sirketi (BIST:PETKM)
Albemarle Corporation (NYSE:ALB)
Linde plc (NASDAQ:LIN)
Gubre Fabrikalari T.A.S. (BIST:GUBRF)
IOL Chemicals & Pharmaceuticals Ltd. (NSE:IOLCP)
PI Industries Limited (NSE:PIIND)
Business
NPK Co., Ltd. is a South Korea-based chemical and advanced materials manufacturer primarily engaged in the development, compounding, and distribution of high-performance plastics, color and functional masterbatches, and specialty nanomaterials. Founded in 1987 and headquartered in Gumi, South Korea, the company operates multiple production and development facilities across Gumi and Pyeongtaek, serving global and domestic clients across the automotive, consumer electronics, industrial manufacturing, healthcare, and telecommunications sectors. The company operates through three principal business divisions: Plastics, Nanotechnology, and RFID/USN Systems. Its core product and service portfolio includes engineering plastic compounds formulated from polypropylene, acrylonitrile butadiene styrene, polybutylene terephthalate, polycarbonate, and polyamide resins tailored for high heat resistance, mechanical strength, and flame retardancy in automotive parts and electronic housings; custom color masterbatches and functional additive masterbatches utilized in polymer processing for films, synthetic fibers, injection-molded products, and industrial containers; advanced nanotechnology solutions comprising conductive nano inks, antibacterial nano-silver polymer masterbatches, and nano-sized metal dispersion agents; and radio-frequency identification tags, readers, and ubiquitous sensor network infrastructure for logistics, healthcare, pharmaceutical tracking, and smart retail inventory management. In recent developments, NPK Co., Ltd. has reinforced its capital allocation and shareholder return strategy through the establishment of treasury share repurchase trust contracts and corporate value-up disclosures. Furthermore, the company has expanded its strategic alliances into biomedical applications by entering into a memorandum of understanding with Hwasun Chonnam National University Hospital for collaborative microbiome-based drug discovery and clinical research, while concurrently accelerating research and development into sustainable, recyclable polymer compounds and automated manufacturing processes.